Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Genuine Parts Company (GPC) Price & Performance

Cassava Sciences IncTrade
Genuine Parts CompanyTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Genuine Parts Company — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Genuine Parts Company trades at $125.23 (market cap $16.65B). The key difference: Genuine Parts Company is far larger — about 313.3× Cassava Sciences Inc's market cap, and Genuine Parts Company pays a 3.51% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAGPC
Market Cap
$53.14M$16.65B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$149.26
52-Week Low
$1.09$92.47
Enterprise Value
-$33.43M$22.87B
Dividend Yield
3.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Genuine Parts Company

Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.

The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC